Monocyte-derived IL-10 Expression Predicts Prognosis of Stage IV Melanoma Patients
Authors:
- Jonathan H. LeeJLJonathan H. Lee
- Young HuynhYHYoung Huynh
- Xing YeXYXing Ye
- Richard EssnerRERichard Essner
- Donald L. MortonDMDonald L. Morton
- 1 November 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 30 (8) , 831-838
Abstract
There are no standard methods to predict response to treatment or outcome of stage IV melanoma. Our previous assessment of peripheral blood mononuclear cells (PBMC) from immunized patients demonstrated that interleukin (IL)-10 expression might be associated with prognosis. However, PBMC are a mixture of CD4+ cells, CD8+ cells, and monocytes. This study identified the subset of PBMC responsible for IL-10 expression and evaluated the prognostic value of IL-10 expression in immunized stage IV patients. Eighty-seven patients with stage IV melanoma were randomly selected from our database. All patients had received an allogeneic melanoma whole-cell vaccine (Canvaxin) after complete resection of clinical disease. Blood samples had been collected serially during Canvaxin administration and cryopreserved. Intracellular IL-10 expression was assessed by double staining fluorescence-activated cell sorter. CD14+ monocytes are the predominant PBMC producing IL-10. Sixteen weeks after treatment (week 16), IL-10 levels were significantly (P=0.02) higher in poor-survival patients than those with favorable outcomes. Patients were separated into 2 groups on the basis of the CD14+ monocyte IL-10 response: either increasing or decreasing IL-10 expression from preimmunization (week 0) to week 16 blood draws. Patients with increasing IL-10 levels had significantly shorter survival than those whose IL-10 levels decreased at week 16 (P<0.0001). Multivariate analysis demonstrated that trends in IL-10 levels inversely correlated with survival (P<0.0001). We conclude that CD14+ monocytes are the dominant cellular source of IL-10 among PBMC and that changes in IL-10 expression may serve as an immunologic-based surrogate for predicting outcome for stage IV patients after surgical resection.Keywords
This publication has 30 references indexed in Scilit:
- Synergistically Upregulated Interleukin-10 Production in Cocultures of Monocytes and T Cells after Stimulation with Respiratory Syncytial VirusInternational Archives of Allergy and Immunology, 2006
- Vaccination: role in metastatic melanomaExpert Review of Anticancer Therapy, 2006
- Cutaneous melanoma: available therapy for metastatic diseaseDermatologic Therapy, 2006
- Prolonged Survival After Complete Resection of Disseminated Melanoma and Active Immunotherapy With a Therapeutic Cancer VaccineJournal of Clinical Oncology, 2002
- Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastasesCancer, 1999
- Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival modelAnnals of Surgical Oncology, 1996
- Generation of mature dendritic cells from human blood An improved method with special regard to clinical applicabilityJournal of Immunological Methods, 1996
- Vaccine therapy for malignant melanomaCA: A Cancer Journal for Clinicians, 1996
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992